for review following a standard timeline, Eisai Co., Ltd. and Biogen Inc. (BIIB) said in a statement. In the U.S., lecanemab was granted accelerated approval as a treatment for Alzheimer's disease ...

WOODCLIFF LAKE, N.J. and KENILWORTH, N.J., Aug. 16, 2018 /PRNewswire/ -- Eisai Inc. and Merck (NYSE: MRK), known as MSD outside of the United Stat ...

At the time, Viehbacher ducked a question about the timeline for the subcutaneous formulation. Eisai is testing the subcutaneous formulation in parallel to a revised intravenous dosing schedule.

cutting several months from its usual review timeline. Leqembi scored its original nod in early January under the agency's accelerated approval pathway. Eisai's new Leqembi application leverages ...